Not Signed In - Mylan Announces Final Approval For Meloxicam Tablets
Sat, 22 Jul 2006 06:00 AM EST
... Mylan Laboratories Inc.(NYSE: MYL) today announced that the U.S. Food and Drug Administration hasgranted final approval for Mylan Pharmaceuticals Inc.'s Abbreviated NewDrug Application for Meloxicam Tablets, 7.5 mg and 15 mg. Meloxicam Tablets are indicated for the relief of the signs andsymptoms of osteoarthritis. [click link for full article] ...
Related Topics
- Meloxicam
- Carbinoxamine and Pseudoephedrine Tablets
- Vaccine Testing & Approval
- Carbinoxamine and Pseudoephedrine Extended-Release Tablets
- Cyanocobalamin Tablets
- Meloxicam Suspension
- Chlorpheniramine, Pseudoephedrine and Hydrocodone Tablets
- Guaifenesin and Dextromethorphan
- Haloperidol Tablets
- Neostigmine Tablets
- Thiabendazole Tablets
- Carbetapentane, Phenylephrine, and Pyrilamine
- Ergoloid Mesylates Sublingual Tablets
- Nystatin Tablets
- Desmopressin Tablets
- Isosorbide Dinitrate, Tablets or Extended-Release Tablets or Capsules
- Tarceva
- Gatifloxacin tablets
- Fenofibrate Tablets
- Pulmonary Fibrosis
email this page
print this page
bookmark this page
feedback on this page
